Payment overview · 2025
General Payments
$147,766.69
165 reported records · 15 companies
Healthcare provider profile · identity verified
Georges Chahoud, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · SAINT LOUIS, MO · NPI 1942390414
Verified facts
What the public records show
CMS Open Payments records show Georges Chahoud, MD received $147,766.69 in general payments during 2025 across 165 reported records.
ABIOMED accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 1014 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lokelma by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 613 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 613 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1502 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABIOMED | Unresolved — no canonical attribution shown | $35,937.40 | 24.3% | 54 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $32,147.45 | 21.8% | 29 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30,852.86 | 20.9% | 23 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $17,177.40 | 11.6% | 13 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14,835.01 | 10.0% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $6,435.32 | 4.4% | 17 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $5,938.07 | 4.0% | 7 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $2,139.81 | 1.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,430.00 | 1.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$275.07 | 0.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $245.43 | 0.2% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $132.06 | 0.1% | 1 | 2025 |
| Impulse Dynamics (USA) Inc. | Unresolved — no canonical attribution shown | $100.69 | 0.1% | 1 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $97.41 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.71 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $62,071.00 | 27 |
| Consulting Fee | $43,332.00 | 11 |
| Travel and Lodging | $16,716.44 | 42 |
| Honoraria | $14,800.00 | 3 |
| Food and Beverage | $7,697.25 | 81 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32,147.45 | 29 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30,852.86 | 23 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $17,177.40 | 13 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $16,265.01 | 10 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $5,938.07 | 7 | 2025 |
Source payment records
|
|||||
| MITRACLIP Normalized: mitraclip |
Device | Abbott Laboratories | $4,470.92 | 6 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $2,017.04 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $1,096.76 | 7 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $510.47 | 2 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $245.11 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $143.73 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $141.37 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $133.70 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $132.06 | 1 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $112.06 | 1 | 2025 |
Source payment records
|
|||||
| Optimizer Normalized: optimizer |
Device | Impulse Dynamics (USA) Inc. | $100.69 | 1 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $97.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1502 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 1014 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 613 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
94 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
1014 | 210 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
613 | 144 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
613 | 144 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1502 | 319 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1727 | 496 |
| Eliquis | Apixaban | 1502 | 319 |
| Spironolactone | Spironolactone | 1120 | 328 |
| Farxiga | Dapagliflozin Propanediol | 1014 | 210 |
| Furosemide | Furosemide | 909 | 294 |
| Entresto | Sacubitril/Valsartan | 769 | 163 |
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 219 |
| Jardiance | Empagliflozin | 613 | 144 |
| Losartan Potassium | Losartan Potassium | 608 | 196 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 553 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 547 | 175 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 486 | 146 |
| Metoprolol Tartrate | Metoprolol Tartrate | 438 | 142 |
| Carvedilol | Carvedilol | 408 | 131 |
| Lisinopril | Lisinopril | 374 | 119 |
| Clopidogrel | Clopidogrel Bisulfate | 369 | 126 |
| Amiodarone Hcl | Amiodarone Hcl | 368 | 102 |
| Warfarin Sodium | Warfarin Sodium | 268 | 72 |
| Torsemide | Torsemide | 235 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 230 | 71 |
| Xarelto | Rivaroxaban | 221 | 53 |
| Hydralazine Hcl | Hydralazine Hcl | 181 | 56 |
| Midodrine Hcl | Midodrine Hcl | 165 | 54 |
| Ranolazine Er | Ranolazine | 143 | 38 |
| Potassium Chloride | Potassium Chloride | 139 | 44 |
| Simvastatin | Simvastatin | 101 | 28 |
| Brilinta | Ticagrelor | 94 | 27 |
| Sotalol | Sotalol Hcl | 78 | 24 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 69 | 12 |
| Nitroglycerin | Nitroglycerin | 67 | 38 |
| Corlanor | Ivabradine Hcl | 56 | 13 |
| Atenolol | Atenolol | 53 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 18 |
| Repatha Sureclick | Evolocumab | 51 | 12 |
| Digoxin | Digoxin | 49 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 49 | 14 |
| Verquvo | Vericiguat | 47 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | 15 |
| Bumetanide | Bumetanide | 39 | 13 |
| Eplerenone | Eplerenone | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 32 | 31 |
| Metolazone | Metolazone | 31 | 11 |
| Dofetilide | Dofetilide | 26 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 16 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Ivabradine Hcl | Ivabradine Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147,766.69 · 165 records | ABIOMED | AMPLATZER AMULET, Barostim Neo System, CARDIOMEMS, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, COREVALVE EVOLUT R, ELIQUIS, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, FARXIGA, FUROSCIX, JARDIANCE, Kerendia, LifeVest, MITRACLIP, Optimizer, SYMPLICITY G3, Senza, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error